No Data
Cognition Therapeutics (CGTX) Gets a Buy From Oppenheimer
Cognition Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Positive Buy Rating Reaffirmed for Cognition Therapeutics Amid Promising Alzheimer's Drug Data
Cognition Therapeutics Presents Poster of Participant Demographics From Phase 2 Dementia With Lewy Bodies Study at CTAD
Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target
B.Riley Financial Maintains Cognition Therapeutics(CGTX.US) With Hold Rating, Maintains Target Price $1
No Data
No Data